Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
even music copyright like Justin Beibier etc .patents worth sold 200 million and LENZ biotech was sold for nothing
Humanigen potential 1 billion sales patent or intellectual property was sold for nothing whereas Justin Beibier's music catalogur or music was worth more than some life saving biotech molecule
if this company was an ADR or business operations was not in the US, the ticker would just get delisted and company don't even bother declaring chapter 11 and not file SEC reports. But because it's assets are registered in US and company employees are US citizens and bank is in the US it had no choice but to do the paper work. the asset LENZ is registered in US patent offices.
As for the technology of LENZ it's just an antidote.
Basically the LENZ intellectual property or any phase 3 drug patent Humanigen had was sold for nothing.
Justine Bieber sold his entire music catalogue for $200 million. The LENZ or any phase 3 drug patents that Humanigen sold for nothing to the stalking bidder. The stalking bidder with the 2 million dollar purchase gets 1.6 million cash accounts receivable and 400 million in cash and deposits and prepayments. it's like buying cash with cash. or buying 2 million worth of gold for 2 million worth of cash.
The law firm was billing humanigen $800/hour so any money this company still has like 12 million in legal liability insurance gets withdrawn quickly. That 2 million is to pay for the wages, and legal bills.. and nothing left for any creditor claims.
what is the point of the March 12 hearing for?
it took 2 months to file chapter 11. 155 documents. and they call this expedited.
and say regular chapter 11 takes 12 months.?
patheon's 25 million dollar creditor claim
chime's 7 million dollar creditor claim
all the creditor get discharged right? that is the point of chapter 11.
With chapter 11 conclusion, does all the fake creditor claim or genuine creditor claims of HGEN Q get discharged and void after emerging from chapter? The company after chapter 11 is a shell company with no employees other than option or claim on future potential profits or revenues of the LENS or ip it sold for nothing to the stalking bidder. a total potential payment of 12 million. assuming it gets FDA approval within 5 years.
The intellectual property or LENZ was acquired for free as the company value the assets as worthless and the market values the shares of HGENQ as worthless not more than 'shell value' for trading purposes.
As for the smuck insurance, HGENQ gets a total of 12 million payment only if the asset they sold becomes successful and makes 1 billion in sales.
As for the 40 million in creditor claims, does all the fake creditor claims get discharged and new emerged HGEN without the Q get zero debt and zero creditor claims
Where the emerged hgen have cash to pay anyone or any employee?
Sales of all assets closed on Feb 20, 2024
The stalking bidder gets all asset including 1.6 million in accounts receivable in Australia.
Basically the company got all the assets for free.
$138,627.14 cash
$348,109.48 deposits and prepayments that they can ask for refund
total assets purchased $486,736.89
What a good deal for the stalking bidder. The IP with so called potential of 1 billion in sales was purchased for nothing.
Management focused on diverse patient enrollment in the LIVE-AIR trial, and discovered an 8-fold improvement in treatment outcomes for Black and African-American patients. The NIH ignored that astounding find.
And now, as we have seen previously from NIH studies, we have this:
"Monday, February 19, 2024
275 million new genetic variants identified in NIH precision medicine data
Study details the unprecedented scale, diversity, and power of the All of Us Research Program...
While more research is needed before these findings can be used to tailor genetic testing recommendations for specific populations, researchers believe the difference in the number of these variants may be influenced by past studies’ limited diversity and their disease-focused approach to participant enrollment, rather than a difference in the prevalence of the variants."
https://www.nih.gov/news-events/news-releases/275-million-new-genetic-variants-identified-nih-precision-medicine-data
Hypocrites. They report their findings, but don't take steps to implement them.
I hope they have success with implementing genetic tests for diverse populations, but authorizing lenz could have a huge impact on diverse covid populations NOW.
https://www.nih.gov/news-events/news-releases/researchers-optimize-genetic-tests-diverse-populations-tackle-health-disparities
Preventable deaths, in our case, are an effect of the government's abuse of discretionary authority, which I was fighting even before my wife's cancer (and covid) diagnoses, and the skin and tissue damage that she suffered from the radiation, which led to a need for wound care.
Preventable covid deaths continue on a daily basis in the US and around the world, and as long as that continues, I will continue to support management's efforts to get lenz authorized or approved.
A thief may demand your money or your life. It takes a special kind of low for government agencies to cause the loss of both.
Watching as this continues to evolve.
Thank You cowtown jay for sharing that with me. I am so sorry to hear about your wife. That really is terrible that she had to suffer when there were treatments like lens being suppressed by the Government in order to push something else onto the masses.
Now I understand why your motivation for lenz to succeed, and why your support for the company remains so strong.
I do have some Good News for you. If you and your wife believe in Jesus Christ and trusted in him then you will see her again.
The next time you will see her again she will be in very good health and youthful again.
This I can promise you.
I've got multiple motivations for wanting lenz to succeed. As a shareholder, and like all of us here, I am financially motivated to see us succeed. But I also feel compelled to focus every bit of light that I can, on the government's abuse of their discretionary authority. This doesn't just apply to the SEC's failure to regulate our equity market, but also applies for the deadly abuse of discretionary authority by Regulatory agencies such as NIAID, the NIH, and the FDA. In addition, once my wife's wound care requirements progressed beyond the point that the visiting nurse could control the wound's progression, my wife had to return to the skilled nursing center in February of 2020. where she remained until her death in Nov 2020, exactly the period that covid arrived in the US, and stretched our health care system to the breaking point. As study after study began to appear thereafter, I knew lenz could have, at least, greatly improved the quality of her remaining life, and I will remain committed to seeing lenz authorized and approved around the world. I can't stand the thought that patients' families are suffering the preventable loss of their loved one's life.
So I remain hopeful to see lenz approved, and I feel confident that management has taken a steadfast, disciplined, methodical approach, to make that happen, against all Big Pharma and Regulatory odds.
I look forward to seeing how management may use their hollowed-out foreign subsidiary. Will this prove to be a merger entity for Taran, as I began talking about over the last month, or so?
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=173637775
I Need a Big Break in Life, and I am Praying You are correct about HGEN my Freind!
To be honest, I think it would take a lot more study for me to feel that I have confidence in making a deduction about HOW these guys have navigated during this bankruptcy. I can't wait to learn as much as I can.
But I have supreme confidence that management has provided the essential ingredients for our explosive success, to include the legal framework, product safety and efficacy, pending corporate structure, regulatory approval, and market penetration. Oh, and that little thing called the recall of our loaned shares. Maybe in the remainder of the week, and hopefully in just one more day, we will finally learn.
I agree and hope they spell it out better in what's going to become of the common shareholders.
There are Excluded Assets in the sale.
"1.2 Excluded Assets. Notwithstanding anything to the contrary in this Agreement, in
no event shall Seller sell, transfer, assign, convey or deliver, or be deemed to sell, transfer, assign,
convey or deliver, and Seller shall retain, all right, title and interest to, in and under any assets
other than the Acquired Assets (collectively, the “Excluded Assets”) including such right, title or
interest in the following:
(g) except with respect to the Foreign Subsidiary, all shares of capital stock,
limited liability company interests, or other equity interests of Seller and each of its respective
Subsidiaries or securities convertible into, exchangeable or exercisable for any such shares of
capital stock, limited liability company interests, or other equity interests;"
pp 45-46/95
https://document.epiq11.com/document/getdocumentsbydocket/?docketId=1061258&projectCode=HUM&docketNumber=155&source=DM
So I disagree with TwongStocks saying that Taran will not be acquiring any equity of HGENQ. I think the above says, in effect, that Taran WILL be acquiring HGEN shares held by Dale's entities.
I think this is saying that shares in HGEN stock are excluded from the the sale to Taran, EXCEPT for those shares held by Dale's entities. I could be wrong, this is a lot of information to process in a compressed time. But it is my best interpretation of what this means. I just hope that the conclusion of the bankruptcy brings about the recall of the loaned shares, and perhaps a bit of additional news.
I think the brokerages could buy-in their customers who are short, without needing current filings, based just on a recall of the loaned shares. The thing is, for me, I just think we are about to see movement on multiple fronts, including an uplisting. So we may, or may not, need news to get the most out of the recall or the uplisting. The delinquent filings could already be completed. We don't have enough details to be able to draw conclusions now. I wouldn't even be speculating at all, if it wasn't for a legitimate concern about the Asset Purchase Agreement. Going that route instead of a buyout never caused me any concern, but I can understand that others can be concerned about that.
I still think we'll have news about a partnership with Novavax, and I still think that an $8B market cap for Humanigen is feasible. And to go even further out on a limb, I still think that Astra-Zeneca could be looking at using lenz with their Covishield vaccine, not just with their and Gracell's CAR-T.
https://www.astrazeneca.com/media-centre/press-releases/2023/astrazeneca-to-acquire-gracell-furthering-cell-therapy-ambition-across-oncology-and-autoimmune-diseases.html
https://en.wikipedia.org/wiki/Oxford%E2%80%93AstraZeneca_COVID-19_vaccine
I hope they then file and bring us current again.
sosjtb,
The question is, what is Humanigen's most valuable asset? I think, for the very near term, it is having a float of 229M shares, which is 110M more shares in the market, than the company has issued. These shares are controlled by Dale's entities, which I view as our financing arm, and as we know, these shares are currently virtually worthless.
But the Asset Purchase Agreement, versus a Buy-Out, does not represent Durrant abandoning those shares, which have been loaned out. They are significantly beneficially owned by Humanigen. I think Humanigen owns 110M of those shares. So it may be that the recall of the loaned shares may be announced by Dale, if not Durrant.
Once, or as, the loaned shares have been recalled, I think we could announce a stock-for-stock merger or business consolidation with Novavax. That will then become our most valuable asset, as it could result in billions of annual revenue dollars, assuming that lenz was integrated into the Novavax prototype vaccine.
I feel like you're calling cadence, and have just ordered the first row of troops to execute a "to the rear, march" command. I certainly feel that positing what I have just sequenced is a dramatic change in course.
The share structure remains intact. You have 4.1M shares of HGENQ now, and you'll still have 4.1M shares of HGEN once the bankruptcy has closed (which will drop the Q suffix).
The way I’m seeing it, Durrant and Tarran get Lenz, we get the debt and what’s left in basically an empty shell.
So, the shares look to stay intact, but who will receive them?
Does the buyer get the shares?
Or do they remain behind under HGEN?
Yes, the deadline to get this wrapped up is Tuesday.
Wow it looks like things are moving along here:
https://stocktwits.com/TwongStocks/message/562064354
https://document.epiq11.com/document/getdocumentsbydocket/?docketId=1061258&projectCode=HUM&docketNumber=155&source=DM
Thank you for that, bencozey. I have followed this company since 2015, when they were known as Kalobios, and issued the first recall of their loaned shares. A few weeks after they became Humanigen in 2017, I bought and have maintained a small position here. In 2022 and 2023, I discontinued selling shares, but continued to add as I could. So I'm really looking forward to the recall of their loaned shares, and seeing my open sell orders filled.
One of the things I'm really going to look forward to will be the financial press interviews of Durrant after what will be our historic short squeeze. I'm sure the press will want to know about the reasons for our delayed regulatory approval, which could have saved millions of lives worldwide if approved earlier, and could have greatly alleviated the trillions of dollars in damage to the world's economies and societies. I'm also sure that the press will want to know how management acquired about a 90% control of the company, and how and why the company acquired that ownership.
The answers could shine a lot of light on the government's deadly abuse of their discretionary authority, and their willful/criminal negligence, in service to their Big Pharma sponsors.
Yes, you have to give Jay a little credibility on what is unfolding. After all, he lived through it once already and he can see it unfolding.
Actually I think it fits perfectly into what Jay has been saying. The share structure is in place and the company has not shut the doors. The company will have future revenues. Next step, call in the loaned shares. I didn't believe Jay, but as time goes by, it does seem recalling the shares is probable
Here are 95 pages telling us we are screwed.
https://document.epiq11.com/document/getdocumentsbydocket/?docketId=1061258&projectCode=HUM&docketNumber=155&source=DM
Taran will pay only 12 million in milestone payments if Lenz is approved…..$12 million! That values HGEN shares at about .10 if all milestone are met and payed within 7 years.
This is toast.
I'm curious about Intracoastal Capital's beneficial ownership statement filed for Baudax, in the week before Dale sold his Baudax shares, which was one day ahead of the Baudax delisting. Will this somehow translate into a gateway for Humanigen to acquire an interest in Tera-Immune through Intracoastal Capital?
https://www.sec.gov/cgi-bin/browse-edgar?company=baudax&match=starts-with&filenum=&State=&Country=&SIC=&myowner=exclude&action=getcompany
I just think that Humanigen has a real interest in Tera-Immune's novel Treg-based cell therapies for autoimmune diseases.
https://www.baudaxbio.com/news-and-investors/press-releases/detail/267/baudax-bio-acquires-teraimmune-inc
The timing is worth noting. If there is a connection between these transactions, maybe we'll find out on or before Monday, when the market is closed. It wouldn't be the first time the company announced major news on a day when the market is closed.
If they would have filed chapter 7 Bankruptcy, I would have been 100% in agreement with you. However, they filed Chapter 11 Bankruptcy which keeps the Share structure intact. If they wanted to destroy the current shareholders, they would have filed for Chapter 7 Bankruptcy which would have wiped the stock out as well.
Even if they do nothing our OS is 119 million shares. For a shell alone this will be worth pennies at very minimum. With the Bankruptcy behind them they will be debt free and this will be very clean going forward.
I too would be very happy with $1, but if we make it to $1 then we are most likely going much higher than that.
I've had a couple of friends who have been telling me about all of the benefits of opening a Roth IRA for quite some time now. My problem was that I have been trading to supplement my pension income. So, a Roth kept me from taking gains right away. Therefor I have not been interested. However, in 2023 I turned 52 and I am getting closer to that 59 1/2.
Then after printing my 1099 forms from my one E-trade account and having 164 pages of trades just on one account that I will have to hand over to my tax guy which he isn't going to be too happy about. I decided maybe I can do some of this day trading for my future and not have to worry about all of the paperwork.
Roth IRA trades do not need to be reported like they do on a regular brokerage. Hopefully this will be a way for me to have some fun trading without the hassle of paperwork and hopefully build Wealth for myself and my family. I probably should have done this a long time ago.
I would like to put 1 million shares of my HGEN in my Roth IRA while it's cheap, but lakers is probably correct about this as he has been doing this much longer than me. I probably won't be able do that transfer from a Non-Roth Brokerage account, and there is no way to liquidate HGEN and then buy it back in the ROTH while it trades on the expert market. so, I will just hold my shares in the regular brokerage account.
You are Absolutely 100% Correct and I wouldn't mind one bit on paying my fair share of capital gains taxes. The Roth IRA for me would be more for "self-control" for me not selling this too early like $1 or $2 dollars per share when it could go over a hundred. Being in a Roth IRA knowing I can't touch it keeps me in check from selling too early. Plus, this will set my family up in case something happens to me.
Welcome to the room, LuckyWanderer21.
I saw shares trade for over $200 per share during the first recall of the company's loaned shares. Of course, price wasn't sustained at that level. Prices dropped as the brokerages bought-in their clients who were short. This was in the November/December 2015 time frame. The chart linked below doesn't quite reflect share prices that high, but I think that's because the chart doesn't reflect data from all of the worldwide exchanges. The highest price I see during the referenced time frame was just over $174.
https://www.google.com/search?q=kalobios+stock+price+history&oq=kalobios+stock+price+history&gs_lcrp=EgZjaHJvbWUyBggAEEUYOTIHCAEQIRigAdIBCjE4Njg1ajBqMTWoAgCwAgA&sourceid=chrome&ie=UTF-8
But I know what prices I saw, up to about $248, as I recall. And those prices were initially charted.
Of course it seems far-fetched. But, in my opinion, the company has been steadily loaning shares in preparation of a second recall of their loaned shares, which I eagerly await.
But, if you have reason to think management has no plan for individual shareholders, please enlighten us. On second thought, don't bother.
Sorry. currently, there’s no plan for individual shareholders, and the stock might vanish. I’m curious, why do some think it’s feasible? $200 per share… Is that really realistic? Personally, it seems far-fetched.
I’d be happy even with $1 per share, but even that seems unlikely. The company doesn’t appear to be doing anything for individual shareholders.
If Jay is right about $200 a shares you shouldn’t be worried about paying your fair share of long term capitol gains taxes on your nearly $1billion profit off a less than $1k investment!
Using a Roth for these speculative stocks is the way to go. Let me share my experience. I've had two scenarios. My accounts are with Schwab. Also, I have been funding, over the years, Roth's for two of my adult children. Now, for my own accounts, I was able to move actual shares owned, from my IRA to my Roth IRA. However, I could not do it online. I had to call Schwab and request it from a live person to make the move. For my adult children, I could not transfer shares from any of my accounts to theirs. I had to put in cash and buy the shares in their accounts. I could transfer cash from my regular brokerage account to theirs after I signed a letter approving it and allowing Schwab to keep it on file for future years. So in some years, I would sell the particular shares in my brokerage account, wait for settlement, transfer it, and buy the shares in their account.
You are most likely right about this. I will let you know if I am able to make the transfer of 1 million shares of my HGENQ from my Brokerage account into my Roth IRA account through E-trade. It would be nice as HGENQ is only worth $400 for 1 million shares at today's prices.
If not it's no big deal as I am holding 4,100,000 shares. So, if cowtown jay is correct about this I will be paying a lot of taxes. LOL :)
I am 99% sure it has to be cash if a new Roth and no other Roth.
I don't see why it has to come from another stock Roth as long as it doesn't exceed the $8000 for 2024? But I will find out soon enough though as I am going to call them tomorrow and see if I can do it.
Through E-trade I set the Stock Roth up along with option trading permission. From what I can see I can transfer internally from my E-trade Brokerage account to my Roth Brokerage account. But then again, the account is still being processed and I cannot transfer anything until it's completed.
You very well maybe correct about me not being able to transfer an existing holding into the Roth Brokerage account.
I won't know until the account is fully active.
I do know I wouldn't dare sell any of my position as I couldn't get it back being that its trading on the expert market.
In 2024 it went from $7500 to $8000. However a million shares of HGEN is only worth $400 at the current pps.
Welcome to the room, lakers17. Could prove to be perfect timing.
I am pretty sure you can't do that. You have to sell and fund the Roth with cash as a contribution for 2023 until April 15th 2024 or for 2024.. Only way you could is in a stock Roth to another stock Roth. $8,000 $8,000 max cash for 2024 if 50 or over. $7,000 for under 50 for 2024. 2023 was $7,500/$6.500.
Followers
|
326
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
43407
|
Created
|
01/31/13
|
Type
|
Free
|
Moderators cowtown jay |
Humanigen, Inc. is a clinical-stage biopharmaceutical company developing its portfolio of next-generation cell and gene therapies for the treatment of cancers via its novel, GM-CSF neutralization and gene-knockout platforms. As a leader in GM-CSF pathway science, we believe that we have the ability to transform CAR-T therapy and a broad range of other T-cell engaging therapies, including both autologous and allogeneic cell transplantation. There is a direct correlation between the efficacy of CAR-T therapy and the incidence of life-threatening toxicities (referred to as the efficacy/toxicity linkage). We believe that our GM-CSF neutralization and gene-editing platform technologies have the potential to reduce the inflammatory cascade associated with serious and potentially life-threatening CAR-T therapy-related side effects while preserving and potentially improving the efficacy of the CAR-T therapy itself, thereby breaking the efficacy/toxicity linkage. Clinical correlative analysis and pre-clinical in vivo evidence points to GM-CSF as the key initiator of the inflammatory cascade resulting in CAR-T therapy’s side-effects. Pre-clinical in vivo data on the neutralization of GM-CSF using antibody or gene KO indicates that it is not required for CAR-T cell activity. Our strategy is to continue to pioneer the use of GM-CSF neutralization and GM-CSF gene knockout technologies to improve efficacy and prevent or significantly reduce the serious side-effects associated with CAR-T therapy.
We believe that our GM-CSF pathway science, assets and expertise create two technology platforms to usher in next-generation CAR-T therapies. Lenzilumab, our proprietary Humaneered® anti-GM-CSF immunotherapy, has the potential to be used in combination with any FDA-approved or development stage CAR-T therapy, as well as in combination with other cell therapies such as HSCT, to make these treatments safer and more effective. In addition, our GM-CSF knockout gene-editing platform has the potential to create next-generation CAR-T therapies that may inherently avoid any efficacy/toxicity linkage, thereby potentially preserving the benefits of the CAR-T therapy while altogether avoiding its serious and potentially life-threatening side-effects.
The company’s immediate focus is combining FDA-approved and development stage CAR-T therapies with lenzilumab, the company’s proprietary Humaneered® anti-human-GM-CSF immunotherapy, which is its lead product candidate. A clinical collaboration with Kite, a Gilead Company, was recently announced to evaluate the use of lenzilumab with Yescarta®, axicabtagene ciloleucel, in a multicenter clinical trial in adults with relapsed or refractory large B-cell lymphoma. The company is also focused on creating next-generation combinatory gene-edited CAR-T therapies using strategies to improve efficacy while employing GM-CSF gene knockout technologies to control toxicity. The company is also developing its own portfolio of proprietary first-in-class EphA3-CAR-T for various solid cancers and EMR1-CAR-T for various eosinophilic disorders. The company is also exploring the effectiveness of its GM-CSF neutralization technologies (either through the use of lenzilumab as a neutralizing antibody or through GM-CSF gene knockout) in combination with other CAR-T, T cell engaging, and immunotherapy treatments to break the efficacy/toxicity linkage including the prevention and/or treatment graft-versus-host disease (GvHD) in patients undergoing allogeneic HSCT. The company has established several partnerships with leading institutions to advance its innovative cell and gene therapy pipeline.
June 15, 2020
Phase 3 Study to Evaluate Efficacy and Safety of Lenzilumab in Hospitalized Patients With COVID-19 Pneumonia
https://clinicaltrials.gov/ct2/show/NCT04351152
Anti-GM-CSF antibodies expected to show better effect in Covid-19 than cytokine-specific targets
July 27, 2020
https://discoverysedge.mayo.edu/2021/06/22/cancer-to-covid-19/
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |